116 results about "Circadian process" patented technology

The present invention provides a light emitting device comprising a first light emitting portion that emits white light at a color temperature of 6000K or more and a second light emitting portion that emits white light at a color temperature of 3000K or less, which include light emitting diode chips and phosphors and are independently driven. The present invention has an advantage in that a light emitting device can be diversely applied in a desired atmosphere and use by realizing white light with different light spectrums and color temperatures. Particularly, the present invention has the effect on health by adjusting the wavelength of light or the color temperature according to the circadian rhythm of humans.

Environmental characteristics of habitable environments (e.g., hotel or motel rooms, spas, resorts, cruise boat cabins, offices, hospitals and / or homes, apartments or residences) are controlled to eliminate, reduce or ameliorate adverse or harmful aspects and introduce, increase or enhance beneficial aspects in order to improve a “wellness” or sense of “wellbeing” provided via the environments. Control of intensity and wavelength distribution of passive and active Illumination addresses various issues, symptoms or syndromes, for instance to maintain a circadian rhythm or cycle, adjust for “jet lag” or season affective disorder, etc. Air quality and attributes are controlled. Scent(s) may be dispersed. Hypoallergenic items (e.g., bedding, linens) may be used. Water quality is controlled. Noise is reduced and sounds (e.g., masking, music, natural) may be provided. Passive and active pathogen controls are employed. Controls are provided for the occupant and / or facility personnel, as is instruction, and surveys, including assessing wellness.

This is a new invention, including improvements upon existing inventions, which is safer, simpler to use, less invasive into a user's daily routine and provides a lower cost solution to existing pulsed magnetic field and related vibrational electromagnetic therapy devices. This invention (apparatus) is referred to as an EnergyWave Therapy Device to distinguish it from existing electromagnetic therapy devices. It operates non-invasively on a homeopathic level to improve sleep, encourage natural healing and reduce pain, swelling, and general discomfort. This is accomplished through different embodiments of the apparatus all of which generate Multiple Simultaneous Extremely Low Frequency (MSELF) energy waves which may be any combination of Alternating Polarity Magnetic Fields (APMF), narrowband near-coherent long-wavelength (580 nm to 980 nm) light emitting diodes (LEDs), or electrical vibrations transmitted through the medium of water using carbon rod electrodes. The MSELF vibrations are derived from a quartz crystal with a fundamental frequency less than one-half of one percent from a natural Fibonacci Sequence Number. The apparatus utilizes firmware operating in a microcontroller containing predefined, user selectable therapy programs either emulating natural Circadian Rhythms for sleep and rest, or other therapeutic programs, all of which contain Electromagnetic Field (EMF) dose limitations to prevent any possible overexposure. The microcontroller is also clocked at the same fundamental frequency generated by the Fibonacci Sequence Quartz Crystal. Additionally, the apparatus's unique application of an H-Bridge configuration power-driver with Pulse Width Modulation (PWM) capabilities supports a novel approach to supply two simultaneous therapeutic frequencies to either a copper-trace coil emitter integrated on the main Printed Circuit Board (PCB) or optional external energy emitters. The result is a more effective, lower energy, safer, lower cost, simpler to use, noninvasive, multi-modal, EnergyWave Therapy Device.

A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity / manifestation of gastric acid secretion (and / or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

The present invention provides a method and composition for treatment of benign prostate hyperplasia (BPH) in men via a transscrotal delivery system. The composition of the present invention includes the steroid hormone progesterone containing permeation enhancers that greatly facilitate permeation through the skin, thus preventing modification of the constituents therein and providing continuous and sustained delivery of progesterone for several hours that mimics the circadian rhythm of endogenous progesterone. The progesterone composition preferably is capable of delivering an effective dosage amount of about 65-100 mg of progesterone per ml when applied directly onto the surface of scrotum.

Systems and methods for treating diseases, addictions and disorders in humans and animals involving synchronizing and tailoring the administration of drug compounds with the body's natural circadian rhythms, in order to counteract symptoms when they are likely to be at their worst. Automated and pre programmable transdermal drug administration system are used. This system can also utilize a pump or pressurized reservoir, and / or a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with micro-fabricated structures commonly referred to as Micro-needles, or heat, or iontophoresis, sonophoresis, or a wide range of chemical permeation enhancers.

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and / or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

The present invention relates to circadian rhythm management. In order to improve circadian rhythm management, an apparatus is provided that uses an alternative exercise-based concept and personalized approach for managing or controlling personal circadian rhythm and optimizing sleep onset.

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity / manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

A functional composition containing as an active ingredient a lactic acid fermented product obtained by fermenting a component of soybean origin using a lactic acid bacterium belonging to the genera Lactobacillus, Leuconostoc, or Pediococcus. It has various activities such as growth hormone secretagogue activity, fatigue accumulation preventing activity, circadian rhythm regulatory activity, reproductive behavior inducing activity, and so forth and is useful as a growth hormone secretagogue, a fatigue accumulation preventing composition, a circadian rhythm regulator, or a reproductive behavior-inducing composition.

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

Systems and methods to provide light therapy to a subject use a light source configured to emit pulses of electromagnetic radiation consisting substantially of blue light. By virtue of the emitted pulses of electromagnetic radiation within a particular range of wavelengths impinging on an eye or eyelid of the subject, the phase of the circadian rhythm of the subject is shifted. Such a shift may be accomplished in such a way that the level of melatonin production is not substantially suppressed.

The present invention provides a non-addictive composition for the treatment of sleep disorders and problems including melatonin, valerian root extract, an antioxidant component, and a vitamin complex component. The present invention further provides a non-addictive composition for the treatment of sleep disorders and problems including melatonin, valerian Root Extract, proanthocyanidin, vitamin E, vitamin B3, vitamin B6, vitamin B12, L-theanine, and magnesium. The present invention also provides a method for treating sleep disorders or problems of a human including administering a non-addictive composition for the treatment of sleep disorders or problems comprising a melatonin, valerian root extract, an antioxidant component, and a vitamin complex component; and causing the circadian rhythm of the human to be normalized and regulated, causing the sleep patterns of the human to be healthy and normal, and causing reduction of stress and anxiety in the human.

The invention discloses a lighting lamp control device which comprises a remote-control transmission circuit, a master control circuit and a drive circuit, wherein the remote-control transmission circuit transmits adjusting signals for adjusting color temperature and luminance of a lighting lamp; the master control circuit decodes the received signals transmitted by the remote-control transmission circuit and transmits the adjusting signals after responding to the adjusting signals of the remote-control transmission circuit; and the drive circuit controls the duty ratio of output PWM (pulse-width modulation) signals to adjust the luminance of the lighting lamp according to an adjusting signal instruction provided by the master control circuit and realizes color temperature adjustment according to different mixed light proportions. The lighting lamp control device and the lighting system have the advantages that illumination level of a ward can be adjusted according different time periods such as in the morning, at noon and at night, a biological rhythm change process is simulated, and illumination intensity and light source color temperature in different time periods can be set according to circadian rhythm demands, so that the illumination intensity and the light source color temperature of the ward can be naturally changed, an optimal rehabilitation lighting effect needed by a patient is achieved, and rehabilitation efficacy of the ward is improved.

The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and / or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and / or treatment.

The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

Methods and compositions for modulating the circadian rhythm of a subject are provided. In practicing the subject methods, modulation of the circadian rhythm of a subject is achieved by administering to the subject an effective amount of at least one of a glucocorticoid receptor antagonist, a CRH antagonist and an MR agonist. Also provided are kits for practicing the subject methods.

A method and a device for ascertaining a fatigue degree of a driver of a vehicle, and to a vehicle, includes a driver-specific ascertainment of a change in the fatigue degree, and ascertaining the fatigue degree based on a previous fatigue degree, which is ascertained utilizing a driver-related circadian rhythm and the ascertained change in the fatigue degree. The method includes the ascertainment of the previous fatigue degree based on data about the driver in a time period during which the driver is not driving the vehicle.

The invention relates to an eye protection desk lamp with a light-emitting diode (LED) light source. The eye protection desk lamp with the LED light source comprises a base, a lamp shade, a connecting body of which the two ends are respectively connected with the base and the lamp shade, a light-emitting body which is arranged in the lamp shade, a driving power supply which is electrically connected with the light-emitting body, and a control device for controlling the driving power supply. The light-emitting body is an LED combined light source and at least comprises a first sub-light source and a second sub-light source, a circadian rhythm-photopic vision (C / P) value of first sub-light source emergent light is more than 2.5, the C / P value of second sub-light source emergent light is less than 2.5, and the control device controls the C / P value of light-emitting light source emergent light to be between the C / P value of the first sub-light source emergent light and the C / P value of the second sub-light source emergent light or to be equal to one of the C / P values. The eye protection desk lamp with the LED light source has the substantial characteristics that: by controlling the intensity of the light of all the sub-light sources of the combined light source, the final total C / P value of the combined light source and the intensity of the light are controlled to change along with the variation of time, the effect of simulating natural light is achieved, and the eye protection desk lamp with the LED light source adapts to the physiological cycle variation of human bodies.

A method for achieving a chronobiologic effect on a circadian rhythm in a human infant or fetus in utero is described. The method involves the administration of melatonin or dose-equivalent melatonin analogue or melatonin receptor agonist to an infant by administering melatonin or dose-equivalent melatonin precursor, melatonin analogue or melatonin receptor agonist to the infant's breast-feeding mother or wet nurse, and to a fetus by administration of melatonin or dose-equivalent melatonin precursor, melatonin analogue or melatonin receptor agonist to the pregnant woman. Alternatives wherein melatonin or dose-equivalent melatonin analogue or melatonin receptor agonist is administered directly to the infant, such as in formula or in expressed breast milk, are also provided.

The invention relates to a low-pressure gas-discharge lamp which, with its light in the red spectral region, influences the biological circadian rhythm by controlling melatonin secretion. The tubular glass discharge vessel, which can also be in the shape of a double helix, is filled with a noble gas or noble-gas mixture and mercury. Electrodes for the supply of energy are arranged at both ends of the discharge vessel. The discharge vessel is multicoated on the inside by phosphor layers applied one after the other. The first phosphor layer located on the glass surface consists of phosphor which is excited both by ultraviolet mercury radiation between 180 nm and 400 nm and also by the blue radiation between 400 nm and 490 nm emitted by the mercury discharge, and by the visible radiation emitted by the second or further phosphor layers between 400 nm and 550 nm, where visible light having emission maxima in the region between 500 nm and 650 nm is generated. In combination with light sources for melatonin suppression, the low-pressure gas-discharge lamp is, with its warm light, particularly suitable for stimulation of the quasi-circadian rhythm in an individual in the absence of external conditions, such as sunlight. Owing to its good colour reproduction and high energy efficiency, it meets all necessary requirements of a light source for illumination tasks and is thus also suitable for general lighting.

A portable, disposable, and self-contained medical device for the production and delivery of therapeutic light to the blood transmitted through the non-ocular skin surface. The light is generated by a chemiluminescent dye configured to radiate light in the specific wavelength required by a particular phototherapy treatment. The wavelength of light emitted by this planar device is such that some disorders of health requiring phototherapy are effectively treated. Disorders falling into this category include elevated bilirubin jaundice, circadian rhythm anomalies, mood disorders and potentially a reduction in injury or surgically related bruise healing time.

The invention discloses a vehicle-mounted device having a driving complete period fatigue level real-time identification and early warning function. The device mainly comprises the following modules: a cumulative driving duration acquisition module which is used for judging the cumulative operation state duration of the vehicle and determining the cumulative driving duration of the driver; a workload acquisition module which is used for judging the high-speed driving cumulative workload of the driver; a GPS module which is used for accurately judging the current moment information; a circadian rhythm acquisition module which is used for judging the circadian rhythm cumulative degree of fatigue of the current driver through a moment information circadian rhythm table; a fatigue degree value calculation module which obtains the fatigue degree value of the driver of any moment; and an early warning module which is used for giving fatigue early warning information. According to the vehicle-mounted device, fatigue level judgment can be performed on any time period in the driving process so that the traffic accident can be reduced to a certain extent, the hazard caused by the traffic accident can be reduced and driving of the driver and public traveling are enabled to be safer.

The invention discloses a circadian rhythm analysis method and belongs to the technical field of human activity analysis. The method includes the steps that firstly, a three-axis acceleration sensor is used for continuous acquisition and downsampling, and three-axis activity amount data of a user is obtained; secondly, according to the three-axis activity amount data, the time when the user goes to bed and the time when the user gets up are obtained; thirdly, the three-axis activity amount from the time when the user goes to bed to the time when the user gets up is intercepted to serve as a sleep data segment; fourthly, sleep characteristic values in the sleep data segment are obtained through analysis; fifthly, according to the sleep characteristic values, the sleep state of the user in the sleeping process is obtained through judgment; sixthly, according to the sleep state, a corresponding circadian rhythm analysis result is output. According to the technical scheme, the method has the advantages that activity time nodes of the circadian rhythm can be more accurately determined, automatic judgment and analysis of the circadian rhythm can be achieved, and perfect reference and suggestions are provided for people to work and rest regularly and live a routine life.